why choose us

Course: Innovative Solutions for Expanding Access to Breast Cancer Care: A Focus on the PI3K/AKT/PTEN Pathway

CME Credits: 1.00

Released: 2026-07-31

In recent years, the PI3K/AKT/PTEN pathway has emerged as an important player in breast cancer development. Up to 50% of patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative (HR+/HER2-) breast cancer have actionable biomarkers within this pathway, paving the way for novel approaches to management. In this online, on-demand CME/CE activity, expert faculty will review available and emerging therapies targeting the PI3K/AKT/PTEN pathway, including the latest clinical trial data. The program will also highlight strategies for managing treatment-related adverse events and the role of the multidisciplinary team in improving care coordination, treatment adherence, and outcomes for patients in community-based settings. This enduring activity is a recorded session from Oncology Congress that took place on June 13, 2026.


Upon completion of this activity, participants should be better able to:


View Full Course